PDCD1 and neoplasm: Importantly, the combination of CDNPs-R848 with an anti-PD-1 mAb (29F.1.A12 clone, 200 μg on day 8–9 following tumor challenge) was synergistic and resulted in a significant tumor reduction in C57BL/6 mice bearing B16F10 melanoma.